TNF and Crohn disease: A meta-analysis was recently carried out looking at the prevalence of RAS in patients with inflammatory bowel disease who were being treated with anti-TNF therapy or anti-integrin therapy.30 It included six studies of patients with Crohn's disease (n = 1,477) and four of patients with UC (n = 267).